CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $80,128,453
- in 11 filings, $80.1M under 10b5-1 plans
Net −$80,128,453. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-12-02 | ASELAGE STEVE Director | Sale | −7,891 | $23.43 | $185K | 202,216 |
| 2020-11-25 | Clague Laura Chief Financial Officer | Sale | −3,750 | $22.72 | $85K | 19,473 |
| 2020-11-24 | Clague Laura Chief Financial Officer | Sale | −3,750 | $23.86 | $89K | 23,223 |
| 2020-11-23 | Clague Laura Chief Financial Officer | Grant or award | +7,500 | 26,973 | ||
| 2020-11-19 | ASELAGE STEVE Director | Gift | −3,000 | 210,107 | ||
| 2020-11-16 | Clague Laura Chief Financial Officer | Sale | −7,500 | $23.98 | $180K | 19,473 |
| 2020-11-16 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −2,500 | $23.98 | $60K | 25,431 |
| 2020-11-16 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −2,500 | $23.96 | $60K | 24,086 |
| 2020-11-13 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −2,500 | $23.62 | $59K | 27,931 |
| 2020-11-13 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −2,500 | $23.62 | $59K | 26,586 |
| 2020-11-13 | Clague Laura Chief Financial Officer | Sale | −7,500 | $23.61 | $177K | 26,973 |
| 2020-11-11 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award | +5,000 | 30,431 | ||
| 2020-11-11 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award | +5,000 | 29,086 | ||
| 2020-11-11 | Clague Laura Chief Financial Officer | Grant or award | +15,000 | 34,473 | ||
| 2020-11-06 | ASELAGE STEVE Director | Sale | −20,625 | $23.00 | $474K | 213,107 |
| 2020-11-05 | ASELAGE STEVE Director | Sale | −2,500 | $21.26 | $53K | 233,732 |
| 2020-10-05 | Heerma Peter Chief Commercial Officer | Sale | −2,188 | $19.35 | $42K | 42,329 |
| 2020-10-02 | Heerma Peter Chief Commercial Officer | Sale | −2,188 | $18.90 | $41K | 44,517 |
| 2020-09-23 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −1,500 | $18.48 | $28K | 24,086 |
| 2020-09-23 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −1,500 | $18.48 | $28K | 25,431 |
Page 40 of 41 · 802 trades